Andrew Donson
Concepts (424)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ependymoma | 27 | 2025 | 165 | 5.350 |
Why?
| | Brain Neoplasms | 44 | 2025 | 1275 | 4.120 |
Why?
| | Infratentorial Neoplasms | 8 | 2025 | 64 | 2.340 |
Why?
| | Glioma | 18 | 2025 | 418 | 2.140 |
Why?
| | Medulloblastoma | 16 | 2025 | 218 | 1.720 |
Why?
| | Astrocytoma | 13 | 2025 | 130 | 1.570 |
Why?
| | Gene Expression Regulation, Neoplastic | 27 | 2025 | 1430 | 1.510 |
Why?
| | Glioblastoma | 14 | 2019 | 334 | 1.370 |
Why?
| | Craniopharyngioma | 7 | 2024 | 78 | 1.360 |
Why?
| | Rhabdoid Tumor | 12 | 2025 | 100 | 1.350 |
Why?
| | Brain Stem Neoplasms | 9 | 2023 | 83 | 1.310 |
Why?
| | Cerebellar Neoplasms | 10 | 2025 | 179 | 1.310 |
Why?
| | Gene Expression Profiling | 26 | 2024 | 1761 | 1.240 |
Why?
| | Pituitary Neoplasms | 5 | 2024 | 194 | 1.030 |
Why?
| | Ganglioglioma | 5 | 2025 | 35 | 0.980 |
Why?
| | Proto-Oncogene Proteins B-raf | 6 | 2025 | 223 | 0.890 |
Why?
| | Biomarkers, Tumor | 13 | 2025 | 1243 | 0.890 |
Why?
| | Central Nervous System Neoplasms | 9 | 2021 | 168 | 0.880 |
Why?
| | Cell Line, Tumor | 29 | 2025 | 3487 | 0.720 |
Why?
| | Drug Screening Assays, Antitumor | 5 | 2021 | 191 | 0.700 |
Why?
| | Teratoma | 7 | 2025 | 121 | 0.690 |
Why?
| | Transcriptome | 12 | 2025 | 1007 | 0.680 |
Why?
| | Radiation Tolerance | 7 | 2025 | 104 | 0.680 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2020 | 76 | 0.630 |
Why?
| | Single-Cell Analysis | 3 | 2025 | 337 | 0.610 |
Why?
| | Neoplasm Recurrence, Local | 8 | 2021 | 1067 | 0.600 |
Why?
| | Child | 49 | 2025 | 22313 | 0.550 |
Why?
| | Cyst Fluid | 1 | 2017 | 21 | 0.540 |
Why?
| | Tumor Microenvironment | 7 | 2025 | 699 | 0.540 |
Why?
| | Antineoplastic Agents | 7 | 2022 | 2156 | 0.510 |
Why?
| | Oligonucleotide Array Sequence Analysis | 19 | 2016 | 757 | 0.490 |
Why?
| | Radiation | 3 | 2021 | 24 | 0.490 |
Why?
| | Humans | 106 | 2025 | 140898 | 0.470 |
Why?
| | Cell Cycle Proteins | 6 | 2022 | 632 | 0.460 |
Why?
| | Chromosomes, Human, Pair 1 | 3 | 2020 | 74 | 0.450 |
Why?
| | Nuclear Proteins | 5 | 2025 | 716 | 0.440 |
Why?
| | Drug Resistance, Neoplasm | 6 | 2025 | 832 | 0.440 |
Why?
| | SMARCB1 Protein | 3 | 2025 | 32 | 0.430 |
Why?
| | Cancer Vaccines | 2 | 2010 | 166 | 0.420 |
Why?
| | DNA Methylation | 7 | 2021 | 640 | 0.410 |
Why?
| | Child, Preschool | 30 | 2025 | 11462 | 0.390 |
Why?
| | Cell Proliferation | 18 | 2025 | 2497 | 0.370 |
Why?
| | Radiation-Sensitizing Agents | 3 | 2016 | 43 | 0.360 |
Why?
| | Epigenesis, Genetic | 5 | 2025 | 655 | 0.360 |
Why?
| | Cytokines | 4 | 2018 | 2092 | 0.360 |
Why?
| | Neoplasm Proteins | 3 | 2012 | 433 | 0.340 |
Why?
| | Apoptosis | 15 | 2025 | 2571 | 0.340 |
Why?
| | Tumor Cells, Cultured | 10 | 2025 | 956 | 0.340 |
Why?
| | Neoplasms, Neuroepithelial | 2 | 2021 | 13 | 0.340 |
Why?
| | Tumor Suppressor Proteins | 2 | 2017 | 325 | 0.330 |
Why?
| | Survivors | 2 | 2023 | 501 | 0.330 |
Why?
| | Chromosome Aberrations | 2 | 2023 | 160 | 0.320 |
Why?
| | Mutation | 9 | 2025 | 3999 | 0.320 |
Why?
| | Prognosis | 15 | 2023 | 4060 | 0.310 |
Why?
| | Supratentorial Neoplasms | 2 | 2021 | 16 | 0.310 |
Why?
| | Protein-Tyrosine Kinases | 4 | 2019 | 430 | 0.310 |
Why?
| | Histones | 4 | 2021 | 638 | 0.300 |
Why?
| | Proto-Oncogene Proteins | 5 | 2022 | 624 | 0.300 |
Why?
| | Oncogene Proteins, Fusion | 2 | 2021 | 197 | 0.300 |
Why?
| | Microarray Analysis | 7 | 2017 | 116 | 0.300 |
Why?
| | Quinazolines | 3 | 2022 | 259 | 0.290 |
Why?
| | Pyrimidines | 6 | 2017 | 508 | 0.280 |
Why?
| | Chromatin | 4 | 2025 | 533 | 0.280 |
Why?
| | MAP Kinase Signaling System | 2 | 2021 | 324 | 0.280 |
Why?
| | NF-kappa B | 3 | 2025 | 690 | 0.270 |
Why?
| | DNA Modification Methylases | 1 | 2007 | 17 | 0.260 |
Why?
| | DNA Repair Enzymes | 1 | 2007 | 29 | 0.260 |
Why?
| | Antineoplastic Agents, Alkylating | 1 | 2007 | 69 | 0.260 |
Why?
| | Chemoradiotherapy | 2 | 2019 | 232 | 0.260 |
Why?
| | Dacarbazine | 1 | 2007 | 95 | 0.260 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 5 | 2020 | 1786 | 0.250 |
Why?
| | Cyclin-Dependent Kinase 6 | 2 | 2020 | 40 | 0.250 |
Why?
| | Chromosomes | 2 | 2024 | 105 | 0.250 |
Why?
| | Immunohistochemistry | 6 | 2017 | 1726 | 0.240 |
Why?
| | B7-H1 Antigen | 2 | 2018 | 224 | 0.240 |
Why?
| | Mice | 17 | 2025 | 18057 | 0.240 |
Why?
| | RNA, Messenger | 8 | 2017 | 2822 | 0.230 |
Why?
| | Chloroquine | 2 | 2017 | 53 | 0.230 |
Why?
| | 12E7 Antigen | 1 | 2025 | 10 | 0.230 |
Why?
| | Infant | 17 | 2020 | 9790 | 0.230 |
Why?
| | Cell Differentiation | 5 | 2025 | 1999 | 0.230 |
Why?
| | Adolescent | 24 | 2025 | 22027 | 0.230 |
Why?
| | Sirtuin 2 | 1 | 2025 | 24 | 0.230 |
Why?
| | Kaplan-Meier Estimate | 5 | 2021 | 907 | 0.220 |
Why?
| | DNA, Neoplasm | 2 | 2020 | 157 | 0.220 |
Why?
| | Cell Cycle | 9 | 2025 | 598 | 0.220 |
Why?
| | Cisplatin | 3 | 2016 | 326 | 0.220 |
Why?
| | Immunophenotyping | 2 | 2017 | 327 | 0.220 |
Why?
| | Macrophage Activation | 1 | 2025 | 200 | 0.210 |
Why?
| | Female | 38 | 2025 | 75540 | 0.210 |
Why?
| | Molecular Targeted Therapy | 3 | 2018 | 418 | 0.210 |
Why?
| | Cellular Senescence | 2 | 2024 | 206 | 0.210 |
Why?
| | Neoplasms, Radiation-Induced | 3 | 2010 | 98 | 0.210 |
Why?
| | Male | 36 | 2025 | 69893 | 0.210 |
Why?
| | Neurofibroma, Plexiform | 1 | 2023 | 12 | 0.210 |
Why?
| | Phagocytosis | 1 | 2025 | 389 | 0.200 |
Why?
| | Neurofibromatosis 1 | 1 | 2023 | 55 | 0.200 |
Why?
| | Receptor, Platelet-Derived Growth Factor alpha | 2 | 2021 | 44 | 0.200 |
Why?
| | Autophagy | 2 | 2017 | 284 | 0.200 |
Why?
| | Transcription Factors | 5 | 2023 | 1703 | 0.190 |
Why?
| | Pyrazoles | 5 | 2022 | 480 | 0.190 |
Why?
| | Survival Analysis | 3 | 2023 | 1320 | 0.190 |
Why?
| | Tamoxifen | 2 | 2004 | 203 | 0.190 |
Why?
| | Proto-Oncogene Proteins c-myc | 2 | 2025 | 163 | 0.190 |
Why?
| | Animals | 19 | 2025 | 37579 | 0.190 |
Why?
| | Cell Survival | 8 | 2020 | 1129 | 0.180 |
Why?
| | raf Kinases | 1 | 2021 | 12 | 0.180 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p15 | 1 | 2021 | 16 | 0.180 |
Why?
| | Indoles | 2 | 2017 | 475 | 0.180 |
Why?
| | Proto-Oncogene Proteins c-mdm2 | 1 | 2022 | 65 | 0.180 |
Why?
| | Sulfonamides | 2 | 2017 | 565 | 0.180 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2021 | 74 | 0.180 |
Why?
| | Neoplastic Stem Cells | 1 | 2025 | 407 | 0.180 |
Why?
| | Receptor, ErbB-3 | 2 | 2015 | 46 | 0.170 |
Why?
| | Receptor, trkC | 1 | 2021 | 10 | 0.170 |
Why?
| | Gene Amplification | 1 | 2021 | 103 | 0.170 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2023 | 210 | 0.170 |
Why?
| | Receptors, Fibroblast Growth Factor | 1 | 2021 | 68 | 0.170 |
Why?
| | Cohort Studies | 9 | 2021 | 5789 | 0.170 |
Why?
| | Receptor, trkB | 1 | 2021 | 35 | 0.170 |
Why?
| | Vaccination | 1 | 2010 | 1467 | 0.170 |
Why?
| | Gene Expression | 4 | 2015 | 1490 | 0.170 |
Why?
| | Jumonji Domain-Containing Histone Demethylases | 1 | 2021 | 63 | 0.170 |
Why?
| | B7 Antigens | 1 | 2020 | 14 | 0.160 |
Why?
| | Polycomb Repressive Complex 1 | 1 | 2020 | 53 | 0.160 |
Why?
| | DNA-Binding Proteins | 3 | 2021 | 1478 | 0.160 |
Why?
| | Anilides | 2 | 2010 | 81 | 0.160 |
Why?
| | Diagnosis, Computer-Assisted | 1 | 2020 | 89 | 0.160 |
Why?
| | Cell Transformation, Neoplastic | 3 | 2019 | 332 | 0.160 |
Why?
| | Phenotype | 5 | 2024 | 3172 | 0.150 |
Why?
| | MicroRNAs | 2 | 2020 | 691 | 0.150 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 7 | 2012 | 985 | 0.150 |
Why?
| | Cell Lineage | 1 | 2021 | 351 | 0.150 |
Why?
| | Isocitrate Dehydrogenase | 2 | 2025 | 67 | 0.150 |
Why?
| | Lymphocytes, Tumor-Infiltrating | 2 | 2012 | 209 | 0.150 |
Why?
| | Genome, Human | 3 | 2021 | 421 | 0.150 |
Why?
| | Pteridines | 2 | 2016 | 21 | 0.150 |
Why?
| | Protein Kinase C | 1 | 2000 | 252 | 0.150 |
Why?
| | Machine Learning | 1 | 2024 | 554 | 0.140 |
Why?
| | Infant, Newborn | 8 | 2020 | 6257 | 0.140 |
Why?
| | Membrane Glycoproteins | 1 | 2021 | 501 | 0.140 |
Why?
| | Antibodies, Monoclonal | 1 | 2025 | 1471 | 0.140 |
Why?
| | Dose-Response Relationship, Drug | 6 | 2017 | 2056 | 0.140 |
Why?
| | ErbB Receptors | 2 | 2015 | 608 | 0.140 |
Why?
| | Stromal Cells | 1 | 2018 | 116 | 0.140 |
Why?
| | Meningioma | 2 | 2009 | 89 | 0.140 |
Why?
| | Adenoviridae | 1 | 1998 | 200 | 0.140 |
Why?
| | SOXE Transcription Factors | 2 | 2016 | 21 | 0.140 |
Why?
| | Drug Approval | 1 | 2018 | 87 | 0.140 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2022 | 526 | 0.140 |
Why?
| | Aging | 2 | 2020 | 1917 | 0.130 |
Why?
| | Transcription Factor RelA | 1 | 2018 | 85 | 0.130 |
Why?
| | Computer Simulation | 2 | 2021 | 1011 | 0.130 |
Why?
| | Macrophages | 1 | 2025 | 1559 | 0.130 |
Why?
| | Genes, p16 | 1 | 2017 | 14 | 0.130 |
Why?
| | Receptors, Interleukin-6 | 1 | 2017 | 46 | 0.130 |
Why?
| | Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2017 | 57 | 0.130 |
Why?
| | E2F Transcription Factors | 1 | 2017 | 62 | 0.130 |
Why?
| | Everolimus | 1 | 2017 | 110 | 0.130 |
Why?
| | Spinal Neoplasms | 1 | 2017 | 36 | 0.130 |
Why?
| | Morpholines | 1 | 2017 | 126 | 0.130 |
Why?
| | Stem Cells | 1 | 2021 | 603 | 0.130 |
Why?
| | Checkpoint Kinase 1 | 1 | 2016 | 28 | 0.130 |
Why?
| | Genetic Therapy | 1 | 1998 | 315 | 0.120 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2018 | 260 | 0.120 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2021 | 873 | 0.120 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2020 | 771 | 0.120 |
Why?
| | Blotting, Western | 6 | 2013 | 1231 | 0.120 |
Why?
| | Myeloid Cells | 2 | 2015 | 149 | 0.120 |
Why?
| | Bone Morphogenetic Proteins | 2 | 2019 | 139 | 0.120 |
Why?
| | Retrospective Studies | 11 | 2020 | 16315 | 0.120 |
Why?
| | EGF Family of Proteins | 1 | 2015 | 17 | 0.120 |
Why?
| | Receptor, EphA2 | 1 | 2015 | 16 | 0.120 |
Why?
| | Neuroectodermal Tumors, Primitive | 2 | 2012 | 11 | 0.120 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2017 | 442 | 0.120 |
Why?
| | Lymphocyte Specific Protein Tyrosine Kinase p56(lck) | 1 | 2015 | 21 | 0.120 |
Why?
| | Pilomatrixoma | 1 | 2015 | 3 | 0.110 |
Why?
| | Flow Cytometry | 3 | 2006 | 1195 | 0.110 |
Why?
| | Radiation, Ionizing | 2 | 2012 | 80 | 0.110 |
Why?
| | Young Adult | 9 | 2021 | 13646 | 0.110 |
Why?
| | Proteins | 1 | 2021 | 1013 | 0.110 |
Why?
| | Disease Models, Animal | 3 | 2021 | 4407 | 0.110 |
Why?
| | Mutation, Missense | 1 | 2016 | 340 | 0.110 |
Why?
| | src-Family Kinases | 1 | 2015 | 94 | 0.110 |
Why?
| | Genetic Variation | 1 | 2019 | 994 | 0.110 |
Why?
| | Activin Receptors, Type I | 1 | 2014 | 7 | 0.110 |
Why?
| | Xenograft Model Antitumor Assays | 3 | 2025 | 903 | 0.110 |
Why?
| | Follow-Up Studies | 6 | 2020 | 5194 | 0.110 |
Why?
| | Drug Delivery Systems | 2 | 2015 | 360 | 0.110 |
Why?
| | Deoxyribose | 1 | 2013 | 6 | 0.100 |
Why?
| | Glutamate-Cysteine Ligase | 1 | 2013 | 19 | 0.100 |
Why?
| | STAT3 Transcription Factor | 1 | 2015 | 211 | 0.100 |
Why?
| | Adult | 16 | 2023 | 39134 | 0.100 |
Why?
| | Acetylcysteine | 1 | 2013 | 144 | 0.100 |
Why?
| | Survival Rate | 4 | 2020 | 1962 | 0.100 |
Why?
| | RNA-Binding Proteins | 2 | 2015 | 447 | 0.100 |
Why?
| | Karyotyping | 4 | 2010 | 104 | 0.100 |
Why?
| | Karnofsky Performance Status | 1 | 2012 | 36 | 0.100 |
Why?
| | Exons | 1 | 2013 | 352 | 0.100 |
Why?
| | Receptors, Opioid | 1 | 2012 | 23 | 0.090 |
Why?
| | Pons | 1 | 2012 | 29 | 0.090 |
Why?
| | Central Nervous System | 1 | 2014 | 264 | 0.090 |
Why?
| | Combined Modality Therapy | 4 | 2019 | 1240 | 0.090 |
Why?
| | Protein Precursors | 1 | 2012 | 134 | 0.090 |
Why?
| | Tomography, X-Ray Computed | 2 | 2020 | 2760 | 0.090 |
Why?
| | Age Factors | 2 | 2017 | 3278 | 0.090 |
Why?
| | RNA, Small Interfering | 2 | 2010 | 624 | 0.090 |
Why?
| | Interleukin-6 | 1 | 2015 | 777 | 0.080 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 2011 | 173 | 0.080 |
Why?
| | Databases, Factual | 1 | 2016 | 1441 | 0.080 |
Why?
| | Protein Kinase Inhibitors | 3 | 2014 | 917 | 0.080 |
Why?
| | Acetaminophen | 1 | 2013 | 264 | 0.080 |
Why?
| | Drug Synergism | 3 | 2017 | 369 | 0.080 |
Why?
| | Epigenomics | 2 | 2021 | 112 | 0.080 |
Why?
| | Risk Factors | 4 | 2020 | 10430 | 0.080 |
Why?
| | Cluster Analysis | 3 | 2021 | 516 | 0.080 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2011 | 211 | 0.080 |
Why?
| | Neoplasm Grading | 2 | 2021 | 309 | 0.080 |
Why?
| | Peripheral Nervous System Neoplasms | 1 | 2009 | 19 | 0.080 |
Why?
| | Spinal Cord Neoplasms | 1 | 2009 | 41 | 0.080 |
Why?
| | Magnetic Resonance Imaging | 2 | 2020 | 3724 | 0.080 |
Why?
| | Poly(ADP-ribose) Polymerases | 1 | 2009 | 100 | 0.080 |
Why?
| | Astrocytes | 1 | 2011 | 216 | 0.080 |
Why?
| | Hemangioma | 1 | 2009 | 45 | 0.080 |
Why?
| | Signal Transduction | 3 | 2025 | 5148 | 0.070 |
Why?
| | T-Lymphocytes | 2 | 2018 | 2003 | 0.070 |
Why?
| | Proportional Hazards Models | 1 | 2012 | 1261 | 0.070 |
Why?
| | Gene Ontology | 2 | 2021 | 52 | 0.070 |
Why?
| | Enzyme Inhibitors | 4 | 2012 | 842 | 0.070 |
Why?
| | Kidney Neoplasms | 1 | 2013 | 400 | 0.070 |
Why?
| | Sarcoma, Ewing | 1 | 2009 | 95 | 0.070 |
Why?
| | Receptor Protein-Tyrosine Kinases | 1 | 2010 | 229 | 0.070 |
Why?
| | Glucose | 1 | 2013 | 1031 | 0.070 |
Why?
| | Herpesvirus 3, Human | 1 | 2011 | 336 | 0.070 |
Why?
| | Herpes Zoster | 1 | 2011 | 319 | 0.070 |
Why?
| | DNA Copy Number Variations | 2 | 2021 | 176 | 0.070 |
Why?
| | Mesenchymoma | 1 | 2007 | 9 | 0.070 |
Why?
| | Nerve Sheath Neoplasms | 1 | 2007 | 11 | 0.070 |
Why?
| | Meningeal Neoplasms | 1 | 2008 | 97 | 0.070 |
Why?
| | Phosphorylation | 3 | 2017 | 1758 | 0.060 |
Why?
| | Aurora Kinases | 3 | 2012 | 28 | 0.060 |
Why?
| | Real-Time Polymerase Chain Reaction | 3 | 2012 | 344 | 0.060 |
Why?
| | Aurora Kinase A | 3 | 2012 | 55 | 0.060 |
Why?
| | Thymidine | 1 | 2006 | 60 | 0.060 |
Why?
| | Etoposide | 1 | 2007 | 163 | 0.060 |
Why?
| | High Mobility Group Proteins | 1 | 2006 | 44 | 0.060 |
Why?
| | Gene Silencing | 1 | 2007 | 197 | 0.060 |
Why?
| | Dose-Response Relationship, Radiation | 2 | 2012 | 143 | 0.060 |
Why?
| | Nerve Tissue Proteins | 1 | 2009 | 605 | 0.060 |
Why?
| | Piperazines | 2 | 2022 | 371 | 0.060 |
Why?
| | Azepines | 2 | 2019 | 97 | 0.060 |
Why?
| | CD47 Antigen | 1 | 2025 | 45 | 0.060 |
Why?
| | In Situ Hybridization, Fluorescence | 3 | 2012 | 308 | 0.060 |
Why?
| | Fatal Outcome | 2 | 2021 | 307 | 0.060 |
Why?
| | Coculture Techniques | 2 | 2011 | 244 | 0.060 |
Why?
| | Pyrimidinones | 2 | 2016 | 122 | 0.050 |
Why?
| | Cell Division | 2 | 2010 | 792 | 0.050 |
Why?
| | Computational Biology | 2 | 2020 | 664 | 0.050 |
Why?
| | Treatment Outcome | 3 | 2024 | 11125 | 0.050 |
Why?
| | Benzamides | 2 | 2017 | 220 | 0.050 |
Why?
| | X-ray Repair Cross Complementing Protein 1 | 1 | 2023 | 13 | 0.050 |
Why?
| | Intelligence Tests | 1 | 2023 | 63 | 0.050 |
Why?
| | RNA, Small Nuclear | 1 | 2023 | 37 | 0.050 |
Why?
| | Fluorouracil | 1 | 2024 | 206 | 0.050 |
Why?
| | Cranial Irradiation | 1 | 2023 | 84 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-sis | 1 | 2023 | 39 | 0.050 |
Why?
| | Quality of Life | 1 | 2015 | 3005 | 0.050 |
Why?
| | Caspases | 1 | 2004 | 245 | 0.050 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2004 | 170 | 0.050 |
Why?
| | Up-Regulation | 2 | 2016 | 856 | 0.050 |
Why?
| | Genomics | 2 | 2021 | 810 | 0.050 |
Why?
| | Cytidine Deaminase | 1 | 2023 | 61 | 0.050 |
Why?
| | Membrane Proteins | 1 | 2009 | 1156 | 0.050 |
Why?
| | Brain Stem | 1 | 2023 | 96 | 0.050 |
Why?
| | RNA | 2 | 2023 | 929 | 0.050 |
Why?
| | G2 Phase Cell Cycle Checkpoints | 1 | 2022 | 44 | 0.050 |
Why?
| | Sequence Analysis, DNA | 2 | 2016 | 817 | 0.050 |
Why?
| | Transcription, Genetic | 2 | 2021 | 1485 | 0.050 |
Why?
| | Septum Pellucidum | 1 | 2021 | 5 | 0.040 |
Why?
| | Cerebellum | 1 | 2023 | 218 | 0.040 |
Why?
| | Middle Aged | 7 | 2021 | 34487 | 0.040 |
Why?
| | Sensitivity and Specificity | 1 | 2006 | 1968 | 0.040 |
Why?
| | Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2021 | 14 | 0.040 |
Why?
| | Histone Deacetylases | 1 | 2023 | 207 | 0.040 |
Why?
| | Ligands | 1 | 2023 | 667 | 0.040 |
Why?
| | Mesencephalon | 1 | 2021 | 66 | 0.040 |
Why?
| | Chromosome Deletion | 1 | 2021 | 118 | 0.040 |
Why?
| | Drug Evaluation, Preclinical | 2 | 2013 | 191 | 0.040 |
Why?
| | Disease Progression | 2 | 2023 | 2791 | 0.040 |
Why?
| | Pancreatic Neoplasms | 1 | 2009 | 889 | 0.040 |
Why?
| | Genetic Heterogeneity | 1 | 2021 | 58 | 0.040 |
Why?
| | Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2021 | 53 | 0.040 |
Why?
| | Neoplasm Staging | 2 | 2017 | 1396 | 0.040 |
Why?
| | DNA Damage | 2 | 2016 | 429 | 0.040 |
Why?
| | Gene Rearrangement | 1 | 2021 | 148 | 0.040 |
Why?
| | Hedgehog Proteins | 1 | 2022 | 200 | 0.040 |
Why?
| | Metabolic Networks and Pathways | 1 | 2021 | 184 | 0.040 |
Why?
| | Vinblastine | 1 | 2020 | 71 | 0.040 |
Why?
| | Preoperative Period | 1 | 2020 | 143 | 0.040 |
Why?
| | Cell Fusion | 1 | 2020 | 50 | 0.040 |
Why?
| | Carboplatin | 1 | 2020 | 145 | 0.040 |
Why?
| | Signal-To-Noise Ratio | 1 | 2020 | 67 | 0.040 |
Why?
| | Repressor Proteins | 1 | 2023 | 428 | 0.040 |
Why?
| | RNA, Neoplasm | 2 | 2009 | 79 | 0.040 |
Why?
| | Cytotoxicity Tests, Immunologic | 1 | 1998 | 38 | 0.040 |
Why?
| | Mice, SCID | 1 | 2019 | 365 | 0.040 |
Why?
| | Neuropsychological Tests | 1 | 2023 | 1089 | 0.040 |
Why?
| | Cell Self Renewal | 1 | 2019 | 54 | 0.040 |
Why?
| | Benchmarking | 1 | 2020 | 179 | 0.040 |
Why?
| | Protein Isoforms | 1 | 2000 | 398 | 0.040 |
Why?
| | Odontogenesis | 1 | 2018 | 11 | 0.040 |
Why?
| | Lysine | 1 | 2020 | 292 | 0.040 |
Why?
| | Laser Capture Microdissection | 1 | 2018 | 32 | 0.040 |
Why?
| | Pyridines | 2 | 2012 | 553 | 0.030 |
Why?
| | In Vitro Techniques | 1 | 2020 | 1093 | 0.030 |
Why?
| | Mice, Inbred NOD | 1 | 2019 | 599 | 0.030 |
Why?
| | Tissue Culture Techniques | 1 | 2018 | 82 | 0.030 |
Why?
| | Treatment Failure | 1 | 1999 | 353 | 0.030 |
Why?
| | Receptors, HIV | 1 | 2017 | 25 | 0.030 |
Why?
| | Down-Regulation | 1 | 2000 | 638 | 0.030 |
Why?
| | Mucin-1 | 1 | 2017 | 21 | 0.030 |
Why?
| | Mechanistic Target of Rapamycin Complex 2 | 1 | 2017 | 62 | 0.030 |
Why?
| | Triazoles | 1 | 2019 | 162 | 0.030 |
Why?
| | Cytogenetic Analysis | 1 | 2017 | 34 | 0.030 |
Why?
| | Fluorescent Antibody Technique | 1 | 2018 | 386 | 0.030 |
Why?
| | Pituitary Gland | 1 | 2018 | 151 | 0.030 |
Why?
| | Immune System | 1 | 1998 | 183 | 0.030 |
Why?
| | Genetic Vectors | 1 | 1998 | 336 | 0.030 |
Why?
| | Interleukin-2 | 1 | 1998 | 451 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2020 | 737 | 0.030 |
Why?
| | Ki-67 Antigen | 1 | 2017 | 111 | 0.030 |
Why?
| | Mice, Nude | 1 | 2019 | 689 | 0.030 |
Why?
| | Mechanistic Target of Rapamycin Complex 1 | 1 | 2017 | 131 | 0.030 |
Why?
| | Glial Fibrillary Acidic Protein | 1 | 2017 | 112 | 0.030 |
Why?
| | Models, Theoretical | 1 | 2020 | 580 | 0.030 |
Why?
| | Cetuximab | 1 | 2017 | 105 | 0.030 |
Why?
| | Neuroglia | 1 | 2018 | 173 | 0.030 |
Why?
| | Benzodiazepinones | 1 | 2016 | 18 | 0.030 |
Why?
| | M Phase Cell Cycle Checkpoints | 1 | 2016 | 24 | 0.030 |
Why?
| | Diagnosis, Differential | 2 | 2012 | 1491 | 0.030 |
Why?
| | Camptothecin | 1 | 2017 | 123 | 0.030 |
Why?
| | Genes, myc | 1 | 2016 | 48 | 0.030 |
Why?
| | Immune Tolerance | 1 | 1998 | 374 | 0.030 |
Why?
| | Microscopy, Confocal | 1 | 2017 | 323 | 0.030 |
Why?
| | Urea | 1 | 2016 | 81 | 0.030 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2019 | 544 | 0.030 |
Why?
| | Mice, Transgenic | 1 | 2021 | 2176 | 0.030 |
Why?
| | Thiophenes | 1 | 2016 | 124 | 0.030 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 1998 | 393 | 0.030 |
Why?
| | Amino Acid Substitution | 1 | 2016 | 309 | 0.030 |
Why?
| | Antigens, CD | 1 | 1998 | 544 | 0.030 |
Why?
| | Transcriptional Activation | 1 | 2017 | 377 | 0.030 |
Why?
| | Amphiregulin | 1 | 2015 | 25 | 0.030 |
Why?
| | Gene Fusion | 1 | 2015 | 22 | 0.030 |
Why?
| | Sequence Analysis, RNA | 1 | 2018 | 447 | 0.030 |
Why?
| | Recombinant Proteins | 1 | 1998 | 1361 | 0.030 |
Why?
| | Mitosis | 1 | 2016 | 197 | 0.030 |
Why?
| | Cell Culture Techniques | 1 | 2017 | 368 | 0.030 |
Why?
| | HeLa Cells | 1 | 2016 | 639 | 0.030 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2015 | 91 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2016 | 713 | 0.030 |
Why?
| | Gene Dosage | 1 | 2015 | 142 | 0.030 |
Why?
| | Inhibitor of Differentiation Protein 2 | 1 | 2014 | 5 | 0.030 |
Why?
| | Inhibitor of Differentiation Protein 1 | 1 | 2014 | 8 | 0.030 |
Why?
| | Smad Proteins | 1 | 2014 | 43 | 0.030 |
Why?
| | Aged | 4 | 2016 | 24666 | 0.030 |
Why?
| | Receptors, IgG | 1 | 2013 | 77 | 0.030 |
Why?
| | Membrane Potential, Mitochondrial | 1 | 2013 | 74 | 0.030 |
Why?
| | Imaging, Three-Dimensional | 1 | 2017 | 566 | 0.030 |
Why?
| | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2013 | 145 | 0.020 |
Why?
| | Phosphoproteins | 1 | 2015 | 335 | 0.020 |
Why?
| | Promoter Regions, Genetic | 1 | 2017 | 1241 | 0.020 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2013 | 335 | 0.020 |
Why?
| | Algorithms | 1 | 2020 | 1763 | 0.020 |
Why?
| | HLA-DR Antigens | 1 | 2013 | 227 | 0.020 |
Why?
| | Catalysis | 1 | 2013 | 320 | 0.020 |
Why?
| | Inflammation Mediators | 1 | 2015 | 517 | 0.020 |
Why?
| | Monocytes | 1 | 2015 | 578 | 0.020 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2015 | 438 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2020 | 3336 | 0.020 |
Why?
| | Colorado | 1 | 2022 | 4597 | 0.020 |
Why?
| | Glutathione | 1 | 2013 | 362 | 0.020 |
Why?
| | Tubulin | 1 | 2012 | 144 | 0.020 |
Why?
| | Acetylation | 1 | 2011 | 245 | 0.020 |
Why?
| | RNA Interference | 1 | 2012 | 468 | 0.020 |
Why?
| | Neural Stem Cells | 1 | 2012 | 159 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2021 | 5895 | 0.020 |
Why?
| | c-Mer Tyrosine Kinase | 1 | 2010 | 41 | 0.020 |
Why?
| | Choroid Plexus Neoplasms | 1 | 2009 | 8 | 0.020 |
Why?
| | Gene Rearrangement, B-Lymphocyte, Heavy Chain | 1 | 2009 | 12 | 0.020 |
Why?
| | Papilloma | 1 | 2009 | 52 | 0.020 |
Why?
| | Kinetics | 1 | 2013 | 1651 | 0.020 |
Why?
| | Zebrafish | 1 | 2014 | 504 | 0.020 |
Why?
| | Immunoglobulin Heavy Chains | 1 | 2009 | 85 | 0.020 |
Why?
| | Poly (ADP-Ribose) Polymerase-1 | 1 | 2009 | 54 | 0.020 |
Why?
| | Epilepsy | 1 | 2013 | 347 | 0.020 |
Why?
| | Gene Knockdown Techniques | 1 | 2010 | 331 | 0.020 |
Why?
| | Antibodies, Neoplasm | 1 | 2009 | 33 | 0.020 |
Why?
| | Single-Blind Method | 1 | 2009 | 289 | 0.020 |
Why?
| | Claudins | 1 | 2009 | 24 | 0.020 |
Why?
| | Cytogenetics | 1 | 2008 | 10 | 0.020 |
Why?
| | Leukocytes, Mononuclear | 1 | 2011 | 572 | 0.020 |
Why?
| | Virus Replication | 1 | 2011 | 531 | 0.020 |
Why?
| | DNA Repair | 1 | 2009 | 239 | 0.020 |
Why?
| | Paresis | 1 | 2007 | 31 | 0.020 |
Why?
| | Biopsy | 1 | 2010 | 1069 | 0.020 |
Why?
| | Craniotomy | 1 | 2007 | 78 | 0.020 |
Why?
| | Hypothalamic Neoplasms | 1 | 2006 | 9 | 0.020 |
Why?
| | Inflammation | 1 | 2018 | 2891 | 0.020 |
Why?
| | Microscopy, Electron | 1 | 2007 | 440 | 0.020 |
Why?
| | Multigene Family | 1 | 2007 | 202 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2013 | 2128 | 0.020 |
Why?
| | Genetic Linkage | 1 | 2006 | 288 | 0.010 |
Why?
| | Neural Crest | 1 | 2006 | 121 | 0.010 |
Why?
| | Genetic Markers | 1 | 2006 | 342 | 0.010 |
Why?
| | Vision Disorders | 1 | 2007 | 167 | 0.010 |
Why?
| | Data Interpretation, Statistical | 1 | 2007 | 374 | 0.010 |
Why?
| | Caspase 3 | 1 | 2004 | 248 | 0.010 |
Why?
| | Enzyme Activation | 1 | 2004 | 801 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2013 | 7899 | 0.010 |
Why?
| | Brain | 1 | 2013 | 2852 | 0.010 |
Why?
| | Genetic Predisposition to Disease | 1 | 2006 | 2368 | 0.010 |
Why?
| | Time Factors | 1 | 2008 | 6944 | 0.010 |
Why?
| | Neoplasms | 1 | 2008 | 2718 | 0.010 |
Why?
|
|
Donson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|